



GOLDFINGER
COMMUNICATIONS

February 16, 2017

Therapix Biosciences to Raise NIS 3.75 million in PIPE Transaction

Therapix Biosciences, a clinical-stage pharma company specializing in the development and commercialization of cannabinoid-based drugs announced that it entered into an agreement with a private investor for the investment of NIS 3.75 million at NIS 0.70 per share.

Proceeds from the transaction will be used for general corporate purposes, including the ongoing Phase II clinical trial of the Company's proprietary entourage technology (THX-TSO1) which is in development for the treatment of Tourette's syndrome, a neurological disorder.

The agreement is subject to certain normal closing conditions, expected to be met within 45 days of the signing date, including receipt of TASE's approval for listing the newly issued shares for trading. According to the agreement, the cash investment will be deposited in escrow at the signing date of the agreement, and will be transferred to the Company subject to the closing thereof.

About Therapix

Therapix is an Israeli-based clinical-stage pharma company focused on the development and commercialization of cannabinoid drugs. The company is listed on the Tel Aviv Stock Exchange and traded over-the counter (OTC) in the United States. Therapix's CEO is Dr. Elran Haber and its Chairman is Dr. Ascher Shmulewitz.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Therapix's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Therapix could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding entering into an agreement with a private investor, the use of proceeds obtained from such investment and the expected closing date of the investment, if at all. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Therapix Biosciences Ltd.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) and in subsequent filings with the SEC. Except as otherwise required by law, Therapix disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

